Research programme: brain-penetrating small molecule therapeutics - Ventus Therapeutics
Latest Information Update: 11 Mar 2024
At a glance
- Originator Ventus Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammation; Neurodegenerative disorders
Most Recent Events
- 28 Feb 2024 Early research in Inflammation in USA (unspecified route) prior to February 2024 (Ventus Therapeutics pipeline, February 2024)
- 28 Feb 2024 Early research in Neurodegenerative disorders in USA (unspecified route) prior to February 2024 (Ventus Therapeutics pipeline, February 2024)